Description: Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of irreversible small molecules to treat patients with genetically defined cancers. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective irreversible inhibitor of MENIN, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was founded in 2017 and is based in Redwood City, California.
Home Page: biomeafusion.com
BMEA Technical Analysis
900 Middlefield Road
Redwood City,
CA
94063
United States
Phone:
650 980 9099
Officers
| Name | Title |
|---|---|
| Mr. Thomas Andrew Butler | Co-Founder, Chairman & CEO |
| Mr. Ramses M. Erdtmann | Co-Founder, Pres, COO & Director |
| Mr. Franco Valle | CFO & Principal Accounting Officer |
| Mr. Heow Tan | Chief Technology & Quality Officer |
| Ms. Naomi Cretcher | Chief People Officer |
| Dr. Thorsten Kirschberg Ph.D. | Exec. VP of Chemistry |
| Dr. Stephan Morris M.D. | Chief Medical Officer |
| Mr. Ravi Upasani | Sr. VP of Intellectual Property |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.4289 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2021-04-16 |
| Fiscal Year End: | December |
| Full Time Employees: | 75 |